Glenn Hanna, MD, and Nabil F. Saba, MD, FACP, discuss recent data on use of tipifarnib in HRAS-mutant head and neck squamous cell carcinoma.
EP. 1: The Evolving Treatment Landscape of HNSCC
A brief overview of treatment advances for HRAS-mutated head and neck squamous cell carcinoma.
EP. 2: Molecular Testing in HNSCC
Guidance for incorporating initial and repeat molecular testing in head and neck cancers into clinical practice.
EP. 3: Tipifarnib in HRAS-Mutated HNSCC
Potential implications for treating patients with HRAS-mutated head and neck cancer with tipifarnib, based on results demonstrated by the RUN-HN study.
EP. 4: Pivotal AIM-HN Clinical Trial of Tipifarnib in HNSCC
Glenn J. Hanna, MD, and Nabil F. Saba, MD, FACP, discuss the design and potential clinical implications of the AIM-HN trial of tipifarnib in head and neck cancers.
EP. 5: Future Directions in HRAS-Mutated Head and Neck Cancer
Glenn J. Hanna, MD, and Nabil F. Saba, MD, FACP, highlight potential new therapies for head and neck squamous cell carcinoma in various patient populations.
EP. 6: Managing Adverse Events With Tipifarnib
Recommendations for mitigating and managing treatment-related adverse events associated with tipifarnib.
Observation Is a Reasonable Alternative to Adjuvant PD-1 Blockade in Stage IIB/IIIC Melanoma
Dr Oluwole on CRS and Neurotoxicity Beyond 2 Weeks After Axi-Cel Infusion in R/R LBCL
Dr Garfall on Ide-Cel and Lenalidomide Maintenance in Myeloma After Suboptimal ASCT Response
Piflufolastat F18 Imaging Is Associated With High Clinician Confidence in Prostate Cancer Management
AUTX-703 Receives FDA Fast Track Designation in Relapsed/Refractory AML
FDA Accepts sBLA for Nivolumab/Ipilimumab in Unresectable/Metastatic MSI-H/dMMR CRC
Anna Parks Receives American Society of Hematology Junior Faculty Scholar Award
Building the Next Generation of Oncology PAs